Filing Details
- Accession Number:
- 0001209191-21-009633
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-11 16:05:52
- Reporting Period:
- 2021-02-09
- Accepted Time:
- 2021-02-11 16:05:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 818686 | Teva Pharmaceutical Industries Ltd | TEVA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1561458 | Hafrun Fridriksdottir | C/O Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva L3 4951033 | Executive Vp, Global R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2021-02-09 | 16,120 | $0.00 | 61,681 | No | 4 | M | Direct | |
| Ordinary Shares | Acquisiton | 2021-02-09 | 67,852 | $0.00 | 129,533 | No | 4 | A | Direct | |
| Ordinary Shares | Disposition | 2021-02-09 | 5,857 | $12.69 | 123,676 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2021-02-09 | 23,639 | $12.69 | 100,037 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Share Units | Disposition | 2021-02-09 | 16,120 | $0.00 | 16,120 | $0.00 |
| Ordinary Shares | Restricted Share Units | Acquisiton | 2021-02-09 | 37,884 | $0.00 | 37,884 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,121 | No | 4 | M | Direct | ||
| 37,884 | No | 4 | A | Direct |
Footnotes
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.
- Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.
- Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject totime-based vesting and will vest on May 11, 2021.
Billionaire Hedge Funds
